Time as Passing in Multiple Sclerosis: In Need of Older Patients

Year 2025, Volume: 8 Issue: 2, 88 - 90, 30.08.2025

Derya Kaya

Abstract

There is no abstract section since this is an editorial paper.

Keywords

late- onset , older adults , multiple sclerosis

Multipl Sklerozda Zaman Geçiyor: Yaşlı Yetişkinlerin İhtiyaçları

Abstract

Keywords

multipl skleroz , geç başlangıçlı , yaşlı bireyler

References

• 1. Isik AT. Covid-19 Infection in Older Adults: A Geriatrician's Perspective. Clin Interv Aging. 2020; 15: 1067-1069.
• 2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372: 1502-1517.
• 3. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020; 26: 1816-1821.
• 4. Prosperini L, Lucchini M, Ruggieri S, et al. Shift of multiple sclerosis onset towards older age. J Neurol Neurosurg Psychiatry. 2022; jnnp-2002-329049.
• 5. Minden SL, Frankel D, Hadden LS, et al. Disability in elderly people with multiple sclerosis: An analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. NeuroRehabilitation. 2004; 19: 55-67.
• 6. Lublin FD, Reingold SC. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996; 46: 907-911.
• 7. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol. 1994; 36: 6-11.
• 8. Trojano M, Liguori M, Bosco Zimatore G, et al. Age-related disability in multiple sclerosis. Ann Neurol. 2002 ;51: 475-480.
• 9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33: 1444-1452.
• 10. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006; 129: 595-605.
• 11. Marrie RA, Horwitz R, Cutter G, et al. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009; 72: 117-124.
• 12. Verbrugge LM, Lepkowski JM, Imanaka Y. Comorbidity and its impact on disability. Milbank Q. 1989; 67: 450-484.
• 13. Chertcoff A, Ng HS, Zhu F, et al. Polypharmacy and multiple sclerosis: A population-based study. Mult Scler. 2023; 29: 107-118.
• 14. Idil E, Aydin AE, Ates Bulut E, Isik AT. Rationally decreasing the number of drugs seems to be a useful therapeutic approach in older adults: 6-month follow-up study. Arch Gerontol Geriatr. 2021; 96: 104472.
• 15. Gelibter S, Saraceno L, Pirro F, et al. As time goes by: Treatment challenges in elderly people with multiple sclerosis. J Neuroimmunol. 2024; 391: 578368.
• 16. Dema M, Eixarch H, Villar LM, et al. Immunosenescence in multiple sclerosis: the identification of new therapeutic targets. Autoimmun Rev. 2021; 20: 102893.
• 17. Musella A, Gentile A, Rizzo FR, et al. Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions. Front Aging Neurosci. 2018; 10: 238.